ACXP — Acurx Pharmaceuticals Cashflow Statement
0.000.00%
- $8.92m
- $5.21m
Annual cashflow statement for Acurx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.6 | -12.7 | -12.1 | -14.6 | -14.1 |
Non-Cash Items | 2.05 | 7.59 | 3.3 | 3.77 | 3.44 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.801 | 0.141 | 1.25 | 1.01 | 0.284 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -3.35 | -5.01 | -7.54 | -9.8 | -10.4 |
Financing Cash Flow Items | 0 | — | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 4.04 | 14.8 | 3.7 | 8.16 | 6.62 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.692 | 9.78 | -3.85 | -1.64 | -3.77 |